AMRX

Amneal Pharmaceuticals' stock price has been impacted by strong Q1 2026 financial results, the acquisition of Kashiv BioSciences, FDA approvals and product launches, and overall stock performance. The company reported robust first-quarter 2026 results, exceeding analyst expectations. Amneal announced an agreement to acquire Kashiv BioSciences for $1.1 billion, which is strategically important for creating a fully integrated global biosimilars leader. Amneal received FDA approval for its first biosimilar medications, Releuko and Alymsys, in 2022. As of May 3, 2024, AMRX stock had risen by 2.89% compared to the previous week and 4.07% over the last month.